Safety and activity of alflutinib in patients with advanced EGFR T790M mutation non-small cell lung cancer who progressed after EGFR-TKI therapy

被引：0

作者：

Shi, Y-K. ^{[1
]}

Zhang, S. ^{[2
]}

Hu, X. ^{[1
]}

Feng, J. ^{[3
,14
]}

Ma, Z. ^{[4
]}

Zhou, J. ^{[5
]}

Yang, N. ^{[6
]}

Wu, L. ^{[7
]}

Liao, W. ^{[8
]}

Han, X. ^{[9
]}

Wang, Z. ^{[10
]}

Zhang, X. ^{[11
]}

Qin, S. ^{[12
]}

Ying, K. ^{[13
]}

Feng, J. ^{[3
,14
]}

Fang, J. ^{[10
]}

Liu, L. ^{[15
]}

Jiang, Y. ^{[16
]}

机构：

[1] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Clin Res Ctr Canc, Dept Med Oncol,Natl Canc Ctr, Beijing, Peoples R China

[2] Capital Med Univ, Beijing Chest Hosp, Dept Oncol, Beijing, Peoples R China

[3] Jiangsu Canc Hosp, Dept Med Oncol, Nanjing, Jiangsu, Peoples R China

[4] Henan Prov Canc Hosp, Dept Resp Med, Zhengzhou, Henan, Peoples R China

[5] Zhejiang Univ, Affiliated Hosp 1, Dept Resp Med, Coll Med, Hangzhou, Zhejiang, Peoples R China

[6] Hunan Canc Hosp, Dept Pulm Oncol, Changsha, Hunan, Peoples R China

[7] Hunan Canc Hosp, Dept Gastroenterol, Changsha, Hunan, Peoples R China

[8] Nanfang Med Univ, Nanfang Hosp, Dept Med Oncol, Guangzhou, Guangdong, Peoples R China

[9] Chinese Acad Med Sci & Peking Union Med Coll, Dept Med Oncol, Beijing Key Lab Clin Study Anticanc Mol Targeted, Natl Canc Ctr,Natl Clin Res Ctr Canc,Canc Hosp, Beijing, Peoples R China

[10] Peking Univ, Dept Pulm Oncol, Canc Hosp, Beijing, Peoples R China

[11] Nantong Tumor Hosp, Dept Med Oncol, Nantong, Peoples R China

[12] Nanjing Univ Chinese Med, Med Oncol, PLA Canc Ctr, Bayi Hosp, Nanjing, Jiangsu, Peoples R China

[13] Zhejiang Univ, Sch Med, Dept Resp Med, Sir Run Run Shaw Hosp, Hangzhou, Zhejiang, Peoples R China

[14] Nantong Univ, Dept Resp Med, Affiliated Hosp, Nantong, Peoples R China

[15] Huazhong Univ Sci & Technol, Union Hosp, Dept Thorac Oncol, Tongji Med Coll,Canc Ctr, Wuhan, Peoples R China

[16] Shanghai Allist Pharmaceut Inc, Clin Affairs & Regulatory Dept, Shanghai, Peoples R China

来源：

ANNALS OF ONCOLOGY | 2019年 / 30卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1531P

引用

页码：629 / 629

页数：1

共 50 条

[1] Role of T790M Mutation in EGFR-TKI Rechallenge for Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer
Zhang, Qiu-Yi
Ke, E-E
Deng, Wei
Niu, Fei-Yu
Zhao, Ning
Su, Jian
Chen, Zhi-Hong
Yang, Jin-Ji
Xu, Chong-Rui
Yan, Hong-Hong
Wu, Yi-Long
Zhou, Qing
JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S271 - S271
[2] Non-invasive and quantitative analysis for EGFR T790M mutation in the patients with advanced non-small cell lung cancer received EGFR-TKI therapy.
Chen, Rui
An, Tongtong
Wang, Jie
Bai, Hua
Wang, Zhijie
Zhao, Jun
Wu, Meina
Zhuo, Minglei
Duan, Jianchun
Wang, Yuyan
Wang, Shuhang
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[3] Non-Small Cell Lung Cancer with Resistance to EGFR-TKI Therapy: CT Characteristics of T790M Mutation-positive Cancer
Koo, Hyun Jung
Kim, Mi Young
Park, Sojung
Lee, Han Na
Kim, Hwa Jung
Lee, Jae Cheol
Kim, Sang-We
Lee, Dae Ho
Choi, Chang-Min
RADIOLOGY, 2018, 289 (01) : 227 - 237
[4] Detection of plasma T790M mutation after the first generation EGFR-TKI resistance of non-small cell lung cancer in the real world
Li, Haiyan
Wang, Jinwei
Zhang, Guojing
Li, Yuping
Lin, Ling
Yang, Haihua
Zhou, Jingjing
Zhang, Lingna
Lv, Dongqing
JOURNAL OF THORACIC DISEASE, 2020, 12 (03) : 550 - 557
[5] Detection of Plasma T790M Mutation After the First Generation EGFR-TKI Resistance of Non-Small Cell Lung Cancer in the Real World
Li, H.
Lv, D.
Xu, H.
Ye, M.
Wu, X.
Kong, F.
Yang, H.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S595 - S596
[6] The Usefulness of "Serum" Samples to Detect EGFR T790M Mutation in EGFR-TKI-Resistant Non-Small Cell Lung Cancer
Kobayashi, K.
Naoki, K.
Ikemura, S.
Yasuda, H.
Kawada, I.
Soejima, K.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S936 - S937
[7] Efficacy and safety of apatinib plus EGFR-TKI in advanced non-small cell lung cancer with EGFR-TKI resistance
Tian, R.
ANNALS OF ONCOLOGY, 2021, 32 : S980 - S981
[8] Immunotherapy-based regimens for patients with EGFR-mutated non-small cell lung cancer who progressed on EGFR-TKI therapy
Qin, Bao-Dong
Jiao, Xiao-Dong
Yuan, Ling-Yan
Wu, Ying
Ling, Yan
Zang, Yuan-Sheng
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (04)
[9] Effect of EGFR-TKI retreatment following chemotherapy for advanced non-small cell lung cancer patients who underwent EGFR-TKI
Guo-Hao Xia
Yun Zeng
Ying Fang
Shao-Rong Yu
Li Wang
Mei-Qi Shi
Wei-Li Sun
Xin-En Huang
Jia Chen
Ji- Feng Feng
Cancer Biology & Medicine, 2014, (04) : 270 - 276
[10] Effect of hydrothorax EGFR gene mutation and EGFR-TKI targeted therapy on advanced non-small cell lung cancer patients
Zhou, Bo
Nie, Jun
Yang, Weidong
Huang, Chenhong
Huang, Ye
Zhao, Hongfei
ONCOLOGY LETTERS, 2016, 11 (02) : 1413 - 1417

← 1 2 3 4 5 →